- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05452083
Postoperative Radiation of Patients With Breast Cancer in Extreme Hypofractionation.
Postoperative External Beam Whole Breast or Chest Wall Irradiation of Patients With Breast Cancer in Extreme Hypofractionation.
연구 개요
상태
정황
상세 설명
The focus of this phase 2-trial is set on feasibility as well as early and late toxicity rates. One possible disadvantage of extreme hypofractionation could be an increased rate of fibrosis within the irradiated region. Therefore, a closer look will be taken with this prospective trial.
In addition, we are planning an accompanying translational research program since hypofractionated schedules are suggested to be more immunogenic in breast cancer.
Secondary objectives therefore are: cosmetic outcome, local tumor control, quality of life, dynamic immune status, importance of tumor infiltrating immune cells, overall survival, disease-free survival, feasibility of breath-hold radiation technique.
연구 유형
등록 (예상)
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Histologically confirmed invasive breast cancer or ductal carcinoma in situ (DCIS)
- pT-category pT0-3
- complete resection (R0)
- Absence of distant metastasis (M0)
- Absence of contralateral breast cancer/ DCIS
- Karnofsky Performance Score ≥ 60%
- Age ≥ 18 years at time of study entry
- Written informed consent
Exclusion Criteria:
- All patients not fulfilling inclusion criteria
- Morbus Paget or pathological skin infiltration
- Earlier or synchronous breast cancer
- Pregnant or breast-feeding women
- Increased radiosensitivity or any genetic disposition for increased radiosensitivity, e.g. ataxia telangiectatica
- Judgement by the investigator that the patient is unlikely to comply with study procedures and requirements
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence and grade of Treatment related adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0)
기간: 08/2022 - 07/2035
|
Evaluation during treatment and at each follow-up visit up to 10 years
|
08/2022 - 07/2035
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cosmetic results according to the Harvard-scale
기간: 05/2022 - 04/2035
|
Clinical evaluation of the irradiated breast at each follow-up up to 10 years according to the Harvard-scale (patient's and physician's view)
|
05/2022 - 04/2035
|
|
In-breast recurrence rate
기간: 05/2022 - 04/2035
|
Evaluation at each follow-up up to 10 years via regular examinations including mammography/ ultrasound
|
05/2022 - 04/2035
|
|
Quality of life during and after treatment using the patient-reported questionnaires EORTC QLQ-C30 and QLQ-BR23
기간: 05/2022 - 04/2035
|
Evaluation of patient's quality of life from inclusion to each follow-up up to 10 years via standardized questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 and the breast-orientated QLQ-BR23
|
05/2022 - 04/2035
|
|
Immune status analysis: Immunophenotyping using peripheral blood at several time points
기간: 05/2022 - 04/2027
|
Withdrawals of whole blood (plasma and serum) before the first irradiation until one year after the treatment.
Immunophenotyping by a modular multicolor flow cytometry-based method.
Furthermore, whole exome sequencing/RNASeq on already obtained tissue from the breast surgery.
|
05/2022 - 04/2027
|
|
Overall survival
기간: 05/2022 - 04/2035
|
Evaluation at each follow-up up to 10 years
|
05/2022 - 04/2035
|
|
Evaluation of feasibility of breath-hold radiation technique throughout the treatment time
기간: 05/2022 - 04/2025
|
Evaluation of patient's capability to follow breathing commandos during planning-CT scan and each application of radiotherapy
|
05/2022 - 04/2025
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .